INTEGRA LIFESCIENCES HOLDINGS CORP

Integra LifeSciences Holdings Corporation announced preliminary unaudited results for the third quarter of 2026, which were impacted by flooding at its Cincinnati facility. The company expects Q3 revenue between $410 million and $412 million, with an estimated $7 million impact from supply disruptions. Adjusted earnings per diluted share are projected to be between $0.55 and $0.59, and operating cash flow is expected to exceed $85 million. The company has updated its full-year 2026 guidance, lowering revenue expectations to $1.634 billion - $1.654 billion and adjusted EPS to $2.30 - $2.40, while maintaining strong operating cash flow projections of $190 million - $200 million. Full manufacturing operations at the Cincinnati facility are anticipated by the second quarter of 2027.

Integra LifeSciences reported Q2 2026 net income of $4.48 million, a significant improvement from a $484.07 million net loss in Q2 2025, which included a substantial goodwill impairment. For the first half of 2026, total revenue increased by 1.6% to $810.68 million, with net loss narrowing to $0.13 million from $509.37 million in the prior year. The company also recognized a $19.0 million IEEPA tariff refund receivable and updated segment names.

Integra LifeSciences reported Q2 2026 revenues of $418.8 million, a 0.8% increase, with adjusted diluted EPS rising 24.4% to $0.56. The company reaffirmed its full-year organic revenue growth and adjusted EPS guidance, while updating reported revenue guidance to reflect a stronger U.S. dollar. Operational progress includes initiating production at its Braintree facility and remaining on track for the SurgiMend® relaunch in Q4.

Integra LifeSciences Holdings Corporation announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will be responsible for leading the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives. She previously served as the interim regulatory leader and has been with Integra since 2021, bringing over 35 years of experience in the healthcare and medical technology industry.

Integra LifeSciences Holdings Corporation announced that Bob Davis, Executive Vice President and President of Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference. The presentation is scheduled for June 16, 2026, at 3:00 PM ET. A live webcast of the event will be accessible on the company's investor relations website.

Integra LifeSciences Holdings Corporation announced that its Chief Financial Officer, Lea Knight, will present at the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for June 3, 2026, at 10:30 AM ET. A live webcast of the event will be accessible on the company's investor relations website under 'EVENTS & PRESENTATIONS'.

Integra LifeSciences Holdings Corporation held its 2026 Annual Meeting of Stockholders on May 7, 2026. Stockholders approved Amendment No. 3 to the 2003 Equity Incentive Plan, increasing the number of shares available for awards by 3,550,000. Additionally, all director nominees were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor, and the compensation of named executive officers was approved on an advisory basis.

Integra LifeSciences Holdings Corporation announced that its Chief Financial Officer, Lea Knight, will present at the BofA Securities 2026 Health Care Conference. The presentation is scheduled for May 12, 2026, at 4:20 PM PT. A live webcast of the event will be accessible via the company's investor relations website.

Integra LifeSciences reported Q1 2026 net revenue of $391.9 million, an increase from $382.7 million in Q1 2025. The company significantly narrowed its net loss to $4.6 million, or $(0.06) per share, compared to a net loss of $25.3 million, or $(0.33) per share, in the prior year period. Additionally, Integra LifeSciences recognized an $18.7 million receivable for IEEPA tariff refunds and detailed an amendment to its Senior Credit Facility in June 2025, which modified Consolidated Total Leverage Ratio covenants. The company also updated its segment names to Specialty Surgery and Tissue Reconstruction.

Integra LifeSciences Holdings Corporation reported its first quarter 2026 financial results, with revenues reaching $391.9 million, an increase of 2.4% on a reported basis and 1.3% organically year-over-year. The company saw an improvement in GAAP diluted EPS to $(0.06) from $(0.33) in the prior year, while adjusted diluted EPS rose to $0.54 from $0.41. Integra LifeSciences reaffirmed its full-year 2026 revenue guidance and raised its adjusted EPS guidance to a range of $2.40 to $2.50, citing benefits from IEEPA tariffs and improved operational performance.